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Abstract
Background: Chlorproguanil-dapsone (Lapdap), developed as a low-cost antimalarial, was withdrawn in 2008 after concerns
about safety in G6PD deficient patients. This trial was conducted in 2004 to evaluate the safety and effectiveness of CD and
comparison with artemether-lumefantrine (AL) under conditions of routine use in G6PD normal and G6PD deficient patients
with uncomplicated malaria in The Gambia. We also examined the effects of a common genetic variant that affects
chlorproguanil metabolism on risk of treatment failure.
Methods: 1238 children aged 6 months to 10 years with uncomplicated malaria were randomized to receive CD or
artemether-lumefantrine (AL) and followed for 28 days. The first dose was supervised, subsequent doses given unsupervised
at home. G6PD genotype was determined to assess the interaction between treatment and G6PD status in their effects on
anaemia. The main endpoints were clinical treatment failure by day 28, incidence of severe anaemia (Hb,5 g/dL), and
haemoglobin concentration on day 3.
Findings: One third of patients treated with AL, and 6% of patients treated with CD, did not complete their course of
medication. 18% (109/595) of children treated with CD and 6.1% (36/587) with AL required rescue medication within 4
weeks, risk difference 12% (95%CI 8.9%–16%). 23 children developed severe anaemia (17 (2.9%) treated with CD and 6
(1.0%) with AL, risk difference 1.8%, 95%CI 0.3%–3.4%, P = 0.02). Haemoglobin concentration on day 3 was lower among
children treated with CD than AL (difference 0.43 g/dL, 95% CI 0.24 to 0.62), and within the CD group was lower among
those children who had higher parasite density at enrolment. Only 17 out of 1069 children who were typed were G6PD A-
deficient, of these 2/9 treated with CD and 1/8 treated with AL developed severe anaemia. 5/9 treated with CD had a fall of
2 g/dL or more in haemoglobin concentration by day 3.
Interpretation: AL was well tolerated and highly effective and when given under operational conditions despite poor
adherence to the six-dose regimen. There were more cases of severe malaria and anaemia after CD treatment although
G6PD deficiency was uncommon.
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Introduction
Chlorproguanil-dapsone (CD) was developed as a low-cost
treatment for uncomplicated malaria [1]. CD was withdrawn in
2008 due to concerns about safety in G6PD-deficient patients [2].
Initial trials showed that CD was well tolerated and effective [3–5].
In a phase 3 trial in children, 96% showed clinical and
parasitological cure by day 14 after the start of treatment, but
children with G6PD A- deficiency were more likely to have a fall
of haemoglobin of 2 g/dL or more by day 3 if they had been
treated with CD, and this association was more marked if baseline
temperature was high [6]. Following this trial, a series of studies
was planned to evaluate the safety and effectiveness of CD in
operational settings in order to evaluate the extent to which the
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risks associated with the use of the drug in settings without G6PD
screening might outweigh the benefits to malaria treatment [7] of
which the present study conducted in 2004 was the only one to be
completed. More recently, two trials of CD combined with
artesunate (CDA) [8.9], showed clearly that malaria patients with
G6PD A- deficiency who were treated with CDA were more likely
to develop severe anaemia following treatment than G6PD
deficient patients treated with SP+AQ [8] or AL [9] and in light
of these findings further development of CDA (Dacart) was
stopped and CD (Lapdap) was withdrawn by GSK [2].
In The Gambia the first line treatment for uncomplicated
malaria was changed from chloroquine (CQ) to sulfadoxine-
pyrimethamine plus CQ in 2004 following the finding of 28%
clinical failure rate in children treated with CQ in 2003 (M Jawla,
unpublished data), and artemisinin combination therapy with
artemether-lumefantrine (AL) was adopted in 2007. The present
trial was conducted in 2004 to evaluate the safety of CD and its
effectiveness in operational settings in comparison with AL, and to
compare effects of these drugs on anaemia in G6PD normal and
G6PD deficient patients with uncomplicated malaria. We also
examined the effects of a common genetic variant that affects
chlorproguanil metabolism on risk of treatment failure. We aimed
to evalue the alternative regimens under conditions as similar as
possible to those of routine use, when doses given at home are not
supervised by trial staff, since adherence may affect outcome [10]
and may vary with drug acceptability and regimen, and absorption
of lumefantrine is affected by diet which is often closely monitored
in trials.
Methods
Study population
Children aged 6months to 10 years presenting with fever or
recent history of fever or other symptoms suggestive of malaria
were screened at three health centres in The Gambia from
October to December 2004 (Farafenni Maternal and Child Health
Clinic, which serves the rural town of Farafenni; Njaba Kunda, a
mission clinic in a rural village; and Brikama Health Centre, a
Government health centre serving a large urban population).
Axillary temperature was measured using a digital thermometer,
the patient was weighed, and a finger prick blood sample was
collected for measurement of packed cell volume, haemoglobin
concentration and malaria microscopy. The study was explained
by a field assistant who sought written consent. Patients were then
assessed by a nurse or clinician (a nurse in 2 sites, a clinician in one
site), and were invited to enrol into the study if they had
monoinfection with P. falciparum with density between 500–
200,000 parasites/mL, PCV $20%, no serious concomitant
illness, and a parent or guardian had given written consent.
Patients were excluded if there were signs or symptoms of severe
malaria (unable to drink or feed, repeated vomiting, convulsions
with the present illness, lethargic or unconscious state, unable to sit
or stand, or parasite density $200,000 asexual parasites/mL of
blood; if they had severe malnutrition, defined as 3SD below
weight for height, clinically evident concomitant disease, or history
of allergy to the study medications, and if travel outside the study
area was planned before the end of the follow-up period. Patients
who did not satisfy the inclusion criteria were treated according to
national guidelines.
Randomization and treatment allocation
The randomization list was produced with Stata version 8
(Statacorp Texas) using permuted blocks of size 10. Eligible
children were allocated to receive three daily doses of CD
(chlorproguanil 2.0 mg/kg and dapsone 2.5 mg/kg body-weight
(manufactured by Wu¨lfing Pharma GmbH, D-31028 Gronau,
Germany and supplied by GlaxoSmithKline, UK), or a six-dose
course of AL (20 mg artemether and 120 mg lumefantrine;
manufactured by Beijing Novartis Pharma Ltd, Beijing, China
for Novartis Pharma AG, Basle, Switzerland and procured
through the World Health Organization (WHO, Geneva). Patients
who were enrolled were issued with an opaque envelope, labelled
with the next sequential study number, containing the treatment
allocation and an appointment card for follow-up visits pre-printed
with the same study number. The children were then referred to a
drug dispenser, a nurse who took no part in patient assessment,
who opened the randomization envelope and supervised admin-
istration of the first treatment dose. Dosages of both medications
were weight-determined according to manufacturers’ weight cut-
off instructions and were dispensed in their original blister packs.
For AL, patients received the World Health Organization (WHO)
weight-specific blister packs as follows: 10.214.9 kg: 1 tablet per
dose;15.0224.9 kg: 2 tablets; 25.0234.9 kg: 3 tablets, and $
35 kg: 4 tablets. The packs contained pictorial instructions on the
regimen schedule. CD was supplied in two formulations: Lapdap
15/18.75, tablets containing 15 mg chlorproguanil hydrochloride
and 18.75 mg dapsone are for use in infants and young children,
white capsule-shaped tablets with a break line on one side for easy
dispensing as half tablet dose and marked CD15 on the other side,
and Lapdap 80/100 tablets containing 80 mg chlorproguanil
hydrochloride and 100 mg dapsone, pink capsule-shaped tablets
indicated for the treatment of older children and adults. Both
tablet formulations have a break line on one side and are marked
with the strength (CD15 or CD80) on the other side. CD was
given according to weight. Children under 16 kg received Lapdap
15 tablets (,8 kg, one tablet; 8–11.9 kg, 1.5 tablets; 12–15.9, 2
tablets). Children 16 kg and over received Lapdap 80 tablets (16–
20.9 kg, 0.5 tablet; 21–39.9 kg, 1 tablet).
The drug dispenser explained the number and timing of
treatment doses to be given, and the first dose of medication was
given by the parent/carer at the health centre under direct
observation. Patients were observed for 30 minutes, and children
who vomited during the observation period had their doses
repeated. If the child vomited both the first and replacement
medication then a rescue medication was given (parenteral
chloroquine plus SP to be taken later). In addition to the study
drugs, oral paracetamol (10 mg/kg) was given in the clinic and
additional doses were given to parents for administration to the
children three times a day at home. Iron tablets (0.5 tablet per day
for children under 5 and 1 tablet per day for older children) to be
taken daily for 2 weeks, were given to children whose PCV at
enrolment was less than 30%.
Follow-up
The parent or carer was encouraged to bring the child back to
clinic if the condition did not improve or if they had any concerns
about the child’s health. Subsequent antimalarial treatment doses
were to be given at home unsupervised. The parent/carer was
requested to return the patient to the clinic on days 14 and 28 after
treatment for clinical evaluation and blood sampling for
measurement of haemoglobin concentration, PCV, malaria
microscopy and parasite genotyping. Children were visited at
home on the day after the regimen should have been completed
(day 3) to ask about compliance with the treatment regimen and
adverse events, and to check for signs of anaemia and haemolysis
(pallor and jaundice). Blister packs were inspected to count left
over medication, and a finger prick blood sample was collected
from the child to measure haemoglobin concentration. Patients
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with severe anaemia (defined as Hb #5 g/dl) or Hb that had
fallen by $2 g/dl from Day 0 measurement were promptly
referred to the clinic for clinical assessment and treatment
(transfusion for severely anaemic children, and iron supplemen-
tation for those with moderate anaemia). Nurses and drivers were
placed on 24-hour emergency duty at the health centres/hospital
where the study was sited to handle emergencies.
Nested case control study
A nested case control study was used to determine whether CD
is less effective in children who when screened carried parasites
with the triple dihydrofolate reductase (DHFR) mutations
encoding isoleucine at position 51 (51I), argentine at position 59
(59R), and asparagines at position 108 (108N). Cases were children
treated with CD who had detectable parasitaemia by day 28, and
controls were children from the same treatment group who
remained P. falciparum negative up to day 28, frequency matched
by centre. In a secondary analysis, a subset of these cases, defined
as children with parasitological treatment failure by day 14, was
used. In addition, for the CD treatment failures, parasites were
typed from samples collected on the day of failure, to detect any
increase in the proportion of children carrying parasites with the
resistant mutations. The same cases and controls were used to
investigate the possible association between CYP2C19 genotype
and CD treatment failure. This cytochrome P450 enzyme is
responsible for activating chlorproguanil. The *2 allele is a
frequently-occurring functional CYP2C19 variant characterised
by a G/A polymorphism in exon 5 which creates an aberrant
splice site. The resulting change in reading frame of the mRNA
introduces a premature stop codon which results in a truncated
and non functional protein [11,12].
Laboratory methods
At screening and at follow-up visits, two thick blood films were
prepared, one was stained with Field Stain and read immediately
for malaria diagnosis for enrolment, the second was dried
overnight and stained with Giemsa for definitive microscopy.
One hundred high power field fields (HPFs) were read before a
slide was declared negative. Parasite density was determined
assuming one parasite per HPF equivalent to 500 parasites/mL
blood [13]. Haemoglobin concentration was measured from finger
prick blood samples using a portable haemoglobin machine
(HemoCue AB, A¨ngelholm, Sweden); samples of blood were
collected into heparinised capillary tubes and spun using a micro-
haematocrit centrifuge (Hawksley, England) to measure PCV.
Using DNA extracted from blood spots, the DHFR codon 51,
59 and 108 alleles were genotyped by polymerase chain reaction
(PCR) amplification followed by analysis restriction fragment
length polymorphism (PCR-RFLP) [14].
G6PD genotype was estimated using an ARMS PCR technique
to detect the two A-associated mutations in G6PD enzyme, an A
to G transition at position 376, encoding the B (normal) to A
change and a G to A transition at position 202, encoding the
specific A- change [15].
CYP2C19 typing was performed using the Taqman real time
PCR technique to detect the *2 allele by the presence or absence
of the A/G polymorphism [16]. We also typed 100 healthy
children for the *3 allele which also results in a non functioning
allele and did not find it in our population.
Endpoints, sample size, and statistical analysis
The primary endpoint was clinical failure by day 28 and change
in haemoglobin between day 0 and day 3. To demonstrate that the
treatments were at least as good as each other assuming a non-
inferiority limit of 3% with at least 80% power at 0.025
significance level, 1180 patients were required to be randomized,
allowing for 10% loss to follow up. Since patients with glucose-6-
phosphate dehydrogenase (G6PD) A- deficiency are more
susceptible to the haemolytic effects of the dapsone component
of CD we were interested in the interaction between G6PD status
and treatment drug in their effects on haemoglobin concentration.
We estimated that a trial of this size would have 80% power (with
a 5% significance level) to detect an interaction between treatment
drug and G6PD status if the average fall in Hb by day 3 was 2 g/
dl in normal patients in both drug groups, and if the fall is 3.1 g/dl
or more in G6PD patients who took CD. Other secondary
endpoints were the overall clinical and parasitological failure rate
(including detection of parasitaemia after day 3), severe anaemia
(Hb#5 g/dL) at any time during the 28-day follow-up, and a drop
to 2 g/dL or more below the screening value at any time during
the 28 days. An analysis plan was written before the treatment
code was linked to the study database.
95% CI for risk differences were computed using a generalised
linear model with an identity link to adjust for centre, in Stata 8.2
(StataCorp, College Station, Texas, USA). Primary analysis was
according to protocol (excluding individuals with no follow-up
data, and according to the treatment drug actually received, but
not excluding children who did not complete the regimen).
Changes in Hb concentration from baseline were compared
between groups by using analysis of covariance, adjusting for the
baseline value as a covariate.
The study protocol was written following the principles of the
Declaration of Helsinki and was reviewed by the MRC Scientific
Coordinating Committee (SCC) and approved by the joint
Gambian Government/MRC Ethics Committee. Meetings were
held in study villages to explain the aims of the study. At the
clinics, the aims and procedures and potential risks were explained
to the mother or carer of children who had screened positive for
malaria, in their usual language, and their signed consent was
sought before the child was enrolled. A Data Safety Monitoring
Board was set up for the trial and an experienced physician, who
was not part of the trial team, was appointed as local safety
monitor to advise on adverse events. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Results
Participant flow
2698 children presenting with fever, history of fever or other
symptoms suggestive of malaria were screened, 1831 (68%) were
positive for P.falciparum, 26 for P.malariae and 2 with P.ovale. Of
those with P falciparum monoinfection, 1238 were enrolled and
randomized to receive AL or CD. Of the remaining 593 who did
not satisfy the inclusion criteria, 251 (42%) had low density asexual
parasitaemia (,500 parasites/mL), 90 (15%) had signs and
symptoms of severe malaria, 55 (9.3%) were severely anaemic
(PCV ,20%). 54 (9.1%) patients were not enrolled because
parents/guardians did not consent to their participation in the
study, 47 had concomitant disease, 42 had very high density
asexual parasitaemia (.200,000 parasites/mL). A total of 1122
(90.6%) patients (560 AL, 562 CD) were seen on day 28. The trial
profile is shown in Figure 1.
4 children randomised to AL who received CD in error and 1
child randomised to CD who received AL, were analysed
according to the treatment received. 56 patients with no outcome
data: 29 withdrew consent to be followed up (17 Co-artem, 12 CD)
and 27 were not contactable due to wrong address or residence
Pragmatic Trial of AL vs CD
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across the Gambian border (14 AL, 13 CD) were excluded from
the analysis. Table 1 shows baseline characteristics of both groups.
234 mainly younger patients were enrolled from Brikama, the
costal site (mean age (standard deviation, SD) 3.9 years, (2.3))
compared with 466 in Farafenni (5.2 years (2.7) and 482 in Njaba
Kunda (5.2 years (2.5), the upcountry sites. Farafenni centre had a
greater proportion of Wolof ethnic patients (22.3%) compared
with Brikama (3.4%) or Njaba Kunda (2.3%). Geometric mean
density of parasitaemia was higher in Njaba Kunda (15 359
parasites/mL of blood) compared with Brikama (24 299/mL) or
Farafenni (30 313/mL.). The prevalence of the G6PD A- genotype
in the patients was 5.2% in Farafenni compared with 3.7% in
Brikama and 3.1% in Njaba Kunda. Patients spent on average 4
days at home before reporting to the health centre in Brikama
compared with 3 days at Farafenni or Njaba Kunda. The
CYP2C19 genotype groups were in Hardy-Weinberg equilibrium
in the study population (X2[1 df] = 0.148, P = 0.7008) with an
allele frequency of 0.168.
Adverse events
There were 44 serious adverse events. 13 children were
admitted with severe malaria (11 in the CD group, and 2 in the
AL group); 23 children had severe anaemia (Hb,5), 17 (2.9%) in
the CD group and 6 (1.0%) in the AL group (risk difference 1.8%,
95%CI 0.3% to 3.4%) and 8 children were hospitalized with other
conditions, not thought to be related to treatment (5 in the CD
group and 3 in the AL group). There were no deaths.
Of the 23 severe anaemia cases, 19 occurred on or before day 3
(15 in the CD group and 4 in the AL group). Children were given
iron and folate to be taken at home. Although transfusion was
recommended for 10/23 children, only 2 of these were transfused,
parents of the other 8 refused. All 23 severe anaemia cases were
seen again on day 14 or 28 and their Hb found to have improved
(range 7.6 g/dL–11.7 g/dL). One child who had Hb of 5.3 g/dL,
and therefore not severely anaemic according to our definition,
was brought back to the clinic on day 2 was transfused. G6PD
genotype was determined for 1069/1238 children. The frequency
of the A- allele was 3.1% (95%CI 2.3% to 4.1%), the genotypes of
boys and girls were in Hardy-Weinberg equilibrium (X2[2] = 0.45,
P= 0.797). Among G6PD normal children, severe anaemia was
detected in 2/507 treated with AL and 12/513 treated with CD.
Among the 49 G6PD A- individuals, 1/24 treated with AL and 3/
24 treated with CD developed severe anaemia; among hemizygous
boys, 2/9 in CD group and 1/7 in the AL group developed severe
anaemia; 5/9 in the CD group had a fall in haemoglobin of 2 g/
dL or more by day 3, compared to 1/6 in the AL group (Table 2).
Figure 1. Trial profile.
doi:10.1371/journal.pone.0017371.g001
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Of the 13 severe malaria cases, 7 occurred in the first 3 days, all
in the CD group. G6PD genotype was obtained for 12 of these
cases, all were normal.
4 children who received AL and 6 who received CD vomitted
the first and repeat dose of study medication on day 1 and were
given rescue treatment.
On day 3, 93 of 601 (15.5%) parents/carers of patients in the
CD group and 25 of 606 (4.1%) in the AL group said their
children were still unwell, the most commonly reported symptoms
were fever, headache, gastrointestinal complains (abdominal pain,
anorexia, and diarrhoea), and cough.
Treatment outcome
109/595 children (18%) in the CD group and 36/587 (6.1%) in
the AL group required rescue treatment within 4 weeks, risk
difference adjusted for centre 13% (95%CI 8.9% to 16%). By day
14, the corresponding rates were 5.8% and 0.9% (Table 3).
Clinical and parasitological failures at days 14 and 28 were
significantly higher in the CD group compared with AL treatment
(p,0.001). There was an increase in mean haemoglobin from
baseline by day 28, with values significantly higher in the AL
group compared with CD treatment. The incidence of anaemia by
day 28, defined as haemoglobin ,5 g/dl, was higher in the CD
group.
Interaction between treatment group and G6PD status
Mean haemoglobin concentration fell after treatment in both
groups, with values in the CD group lower on day 3 than those in
the AL group (a difference, after adjustment for baseline, of
0.34 g/dL, 95% CI 0.18 to 0.49, p,0.001). To determine
whether CD treatment increased the risk of anaemia among
G6PD deficient patients, the interaction between treatment group
and G6PD status in their effects on Hb concentration on day 3
needs to be examined. G6PD genotype was determined for 1069
Table 1. Characteristics of patients at enrolment.
Variable AL (n =618) CD (n=620)
Gender Male:Female 281 (45%):337 (55%) 329 (53%):291 (47%)
Age (in months) mean (range) 60 (6–132) 58 (6–120)
Ethnic group: Mandinka 409 (66%) 404 (65%)
Fula 80 (13%) 73 (12%)
Wollof 79 (13%) 66 (11%)
Others 50 (8.1%) 77 (12%)
Temperature (uC) mean (range) 37.9 (35.1–40.6) 37.9 (35.0–40.7)
Geometric mean parasite density per mL (interquartile range) 21670 (9000–65000) 23007 (9000–71500)
Gametocyte prevalence 20 (3.2%) 35 (5.7%)
Days since onset of symptoms mean (interquartile range) 2.7 (2–3) 2.9 (2–3)
Haemoglobin g/dL mean (range) 10.1 (4.8–15.6) 10.1 (5.3–14.5)
Packed cell volume % mean (range) 31.5 (20–84) 31.3 (15–42)
G6PD A- (hemizygous boys and heterozygous and homozygous girls)* 25/532 (4.7%) 24/537 (4.5%)
Hemizygous males 7 9
Heterozygous Females 17 15
Homozygous females 1 0
Centre: Farafenni 252 (41%) 252 (41%)
Centre: Njaba Kunda 242 (40%) 243 (40%)
Centre: Brikama 124 (20%) 125 (20%)
*G6PD genotype was available for 1069 individuals.
doi:10.1371/journal.pone.0017371.t001
Table 2. Incidence of severe anaemia after treatment according to G6PD genotype.
G6PD genotype Incidence of severe anaemia
% with drop in Hb by day 3 of 2 g/dL or more from
baseline
AL CD AL CD
Normal 2/507 (0.39%) 12/513 (2.3%) 152/491 (31%) 202/495 (41%)
Heterozygous girls 0/17 (0%) 1/15 (6.7%) 6/17 (35%) 7/15 (47%)
Homozygous girls 0/1 - 1/1 -
Hemizygous boys 1/7 (14%) 2/9 (22%) 1/6 (17%) 5/9 (56%)
Not typed 3/82 (3.7%) 2/83 (2.4%) 17/79 (22%) 27/74 (36%)
doi:10.1371/journal.pone.0017371.t002
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of 1238 (86%) children. Boys carrying the A- allele, and girls
homozygous or heterozygous for the A- allele, were identified and
classified by DNA genotyping. Hb concentration on day 3 was
lower in G6PD A- than in G6PD wild type children, and was
lower in children treated with CD than those who received AL,
but the number of A- children was too small to evaluate the
strength of interaction. When the analysis was limited to G6PD A-
deficient hemizygous boys and to the one homozygous girl
identified, (thus excluding heterozygous girls who may not be
deficient) similar results were obtained; in this subgroup, Hb was
slightly lower in the CD group at baseline (9.3 g/dL on day 0
compared to 10.4 g/dL in the AL group); on day 3 the
corresponding mean values were 7.2 g/dL and 8.6 g/dL.
Effect of baseline parasite density
Children with higher parasite densities on day 0 were at
increased risk of anaemia after treatment. This effect was evident
in both drug groups at day 3 and day 14, and on day 3 appeared to
be more marked in the CD group (for anaemia on day 3, the
interaction between treatment group and parasite density group
(above or below the median value 28000 parasites/mL) is 0.41/dL,
95%CI 0.10 to 0.71, P= 0.009), Table 4. Higher parasite density
was associated with higher temperature at screening, but screening
temperature was not independently associated with anaemia.
Adherence to treatment regimen
Of children in the AL group whose mothers were interviewed
about compliance, 402/600 (67%) took all 5 doses at home, 190
(32%) took some but not all the recommended doses at home, 7
(1.2%) took no medication at home. There was no association of
compliance with outcome (data not shown). When blister packs
were inspected 186/591 (31%) of those whose packs were seen had
left-over medication. Of 599 children in the CD group with
compliance information, 562 (94%) took all 3 doses, 12 (2%) took
no doses at home, 25 (4%) took only 1 dose at home. The poorer
compliance with the AL regimen primarily reflects the larger
number of doses. Again no association of compliance with
outcome was evident. 51/568 (9%) whose blister packets were
Table 3. Treatment failure and anaemia outcomes by treatment group: percentage for failures and anaemia; mean (g/dL) for
haemoglobin.
Variable AL (n=587) CD (n=595) Difference (95% CI)* P-value*
Clinical failure by day 14 0.9% 5.8% 5.1% (3.1,7.2%) ,0.001
Clinical failure by day 28 6.1% 18.3% 12.6% (8.9,16.2%) ,0.001
Parasitological failure by day 14 2.2% 8.5% 6.5% (4.0,9.1%) ,0.001
Parasitological failure by day 28 12.9% 38.4% 25.6% (20.9,30.4%) ,0.001
Anaemia drop of 2 g/dL or more from baseline 8.5% 11.8% 1.7% (20.2,3.6%) 0.072
Severe anaemia (Hb,5 g/dL) by day 28 6 (1.0%) 17 (2.9%) 1.8% (0.3%,3.4%) 0.022
Severe malaria by day 28 2 (0.3%) 11 (1.8%) 1.5% (0.3%,2.7%) 0.0129
Mean Hb g/dL day 3# 8.8 8.4 20.35 (20.50,20.20) ,0.001
Mean Hb g/dL day 14# 10.3 10.1 20.19 (20.37,20.01) 0.039
Mean Hb g/dL day 28# 10.9 10.6 20.27 (20.45,20.10) 0.002
Serious adverse events 11 (1.9%) 33 (5.6%) 3.7% (1.5%25.8%) 0.0009
*Adjusted for centre.
#differences adjusted for Hb on day 0.
doi:10.1371/journal.pone.0017371.t003
Table 4. Haemoglobin concentration (g/dL) on day 3 after treatment in relation to G6PD status and parasite density at enrolment.
Mean Hb on day 0 g/dL (no. of
children) Mean Hb on day 3 g/dL
Difference in day 3 Hb
between groups (AL-CD),
(95%CI), adjusted for
baseline*
G6PD genotype: AL CD AL CD
G6PD normal 10.2 (505) 10.1 (509) 8.9 8.5 0.34a (0.18,0.50)
A- hemizygous boys and heterozygous and
homozygous girls
9.8 (24) 9.7 (24) 8.3 7.8 0.32b (20.40,1.0)
A- hemizygous boys and homozygous girls 10.4 (7) 9.3 (9) 8.6 7.2 0.55c (20.69,1.8)
Parasite density at enrolment:
Low: ,median 10.0 (259) 10.1 (257) 8.9 8.8 0.12d (20.08,0.33)
High: .median 10.3 (255) 10.2 (260) 8.8 8.2 0.56e (0.36,0.76)
*Estimate of b-a, representing the interaction between G6PD status and treatment, is 20.04 g/dL, 95%CI 20.78 to +0.69, P = 0.907. If the heterozygous girls are
excluded, (comparison c-a) the estimate is 0.21 g/dL (21.1 to 1.5) P = 0.755. Estimate of e-d representing the interaction between treatment group and parasite density
group is 0.41 g/dL (0.10 to 0.71) P = 0.009.
doi:10.1371/journal.pone.0017371.t004
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inspected had left-over medication. The most common reason
given for not giving treatments at home was that the mother forgot
or did not understand the regimen.
Nested case control study
Of 229 cases, 8 individuals were excluded because they did not
receive CD: 6 vomitted study medication and repeat dose and
were given rescue medication and 2 assigned to CD received AL in
error, leaving 214 cases, and 206 controls. Parasite DHFR
genotyping data was obtained from the three polymorphisms
(codons 51, 59 and 108) for 181/214 cases and 170 controls
frequency matched on centre. 161/181 (89%) cases were positive
for the triple DHFR resistant allele (51I, 59R, and 108N) when
enrolled compared to 146/170 (86%) among controls (odds ratio
1.3 (95%CI 0.7–2.5) P = 0.404). Considering parasitological
failures by day 14, 51/54 (94%) of treatment failures were positive
for the triple DHFR mutation compared to 146/170 (86%) among
controls, odds ratio adjusted for centre 3.0 (95%CI 0.85–10,
P = 0.088). 111 of the parasitological failures by day 28 were typed
on both the day of screening and the day of failure. On day 0, 97/
111 (87%) were positive for the triple mutation, on the day of
failure, 134/139 (96%) were positive, a significant increase
(McNemar X2 6.25 (1df) p = 0.0124).
CYP2C19 genotype. All 214 cases and 206 controls were
typed. There was no association between CYP2C19*2 genotype
and treatment failure. 28% of cases and 29% controls were
heterozygous for the CYP2C19*2 allele (odds ratio for treatment
failure compared to wild type 1.06 (0.69–1.62) P = 0.803, and
2.9% and 2.3% respectively were homozygous (odds ratio 0.81
(0.24–2.72) P= 0.731). Similar results were obtained when cases
were defined as parasitological failures by day 14.
Discussion
This study, conducted as far as possible under conditions similar
to those of routine use of drug treatments by nurses in rural clinics,
showed that CD was less effective than AL, there were more early
returns to clinic, and higher incidence of severe malaria cases and
severe anaemia after treatment, although the frequency of G6PD
deficiency was low. In our study only 17/1069 (1.6%) subjects
were A- deficient (1 homozygous girl and 16 hemizygous boys).
AL, although given without food and with doses other than the
first unsupervised, was well tolerated and highly effective among
children from 6 months to 10 yrs of age.
Assessment of the safety of antimalarials is complicated when
potential side effects of the drugs are also symptoms of the illness,
and is complicated further when the risk of adverse reactions is
confined to a relatively small subgroup of patients. CD was
developed by a public-private partnership as a low-cost treatment
for uncomplicated falciparum malaria [1,17,18]. The factory price
of CD (US$ 0.09 per course for children and $0.29 for adults)
made it an affordable alternative to CQ and SP. The combination
of two drugs with short half lives minimised the selection for
resistance. Concerns were raised about its safety in severely
anaemic and G6PD-deficient patients in a review [19–21] which
concluded that the information on the safety of CD was too limited
to warrant its widespread and uncontrolled use. Dapsone can
produce dose-related haemolysis that can be severe in patients
with G6PD deficiency, but data about the toxic dose in G6PD
deficient subjects were limited, (based primarily on data [22] from
5 G6PD deficient male inmates of Illinois State penitentiary given
daily doses over 21 days). Two more recent trials of CD combined
with artesunate (CDA), in areas where G6PD deficiency is more
common, have clearly shown that there is a substantially increased
risk of severe anaemia with CD for G6PD A- patients [8,9] and for
this reason CD was withdrawn and the development of CDA was
not taken further [2,35].
In our study anaemia after treatment was more common with
CD, but the low frequency of the G6PD A- genotype limited the
power of our study to assess this interaction with genotype. In the
normal pattern of G6PD deficiency no evidence of haemolysis is
apparent until 48–72 hours after substance ingestion [23,24], we
therefore measured haemoglobin concentration on all patients on
day 3 after treatment. The nadir of haemoglobin concentration in
the trial of Premji et al. [8] was at day 7 so it is possible we would
have seen more marked effects if we had sampled on day 7. We
found evidence of an interaction of treatment group with parasite
density, suggesting that failure to rapidly eliminate parasitaemia
may have explained the anaemia after CD in G6PD normal
subjects.
In sub-Saharan African populations, the most common G6PD
deficiency is due to the A- allele with 12% enzymatic activity.
G6PD A- is present at high frequencies in many sub-Saharan
African countries (e.g. 28 % in Nigeria, [25]). The A- differs from
the B (wild type) by two genomic mutations: at nucleotide position
376 A.G with aminoacid change 126 Asn.Asp (G6PD A allele
with 85% enzymatic activity), and at nucleotide 202 G.A with
aminoacid change 68 Val.Met [26]. However it was recently
found that in West Africa the A- allele can also occur with a 968
T.C (323 Leu.Pro) mutation; the 968C was initially found in
Senegal, attaining 10% frequency in the Serere ethnic group [27].
It has subsequently been reported that the 968C mutation is
present in 8% Gambians, which, combined with a 3% frequency
of 202A yields an overall A- frequency of 11% [28]. Although in
our study we typed only the 202G.A (the 968C mutation was
unreported when our study took place), 5 out of 9 G6PD A-
hemizygous males had a drop of 2 g/dL or more in haemoglobin
concentration by day 3 after taking CD while only 1 out of 6 who
took AL did, consistent with conclusion from other studies
[8,9,22,29] that dapsone induces haemolysis in G6PD deficient
individuals.
The G6PD ARMS assay used in our study was validated on 100
different G6PD 202 genotypes by an RFLP- based assay [15].
Although Guindo et al. have reported G6PD 202 frequencies of
more 10% in Malinke people (Malian Mandinka) [33] the
frequency of this mutation in Gambians is considerably lower, as
also confirmed by Clark et al. [28]. The difference in frequency of
G6PD deficiency between these populations can be explained by
several factors, including admixture and drift, given the historical
separation of West African ethnic groups, even when derived from
a common ancestral population.
Treatment failure rates after CD in our study were high but not
dissimilar to those found in other studies, a comparable CD
parasitological failure rate, mainly attributed to reinfections, has
been reported from Kilifi District Hospital, Kenya, where a
randomised trial of CD using a similar study design in children
aged 6 months-5 years with uncomplicated malaria resulted in day
28 parasitological failure in 41% (95% CI 33–49) [3]. In that
study, a lower dose (chlorproguanil-dapsone 1.2 and 2.4 mg/kg
body weight) was used and no adverse events were reported. The
multi-centre efficacy trial, using the same dose formulation of CD
as we used in our trial documented day 14 parasitological failure in
4% of patients aged 1–10 years compared to 5.8% in our study [6]
(patients in that study were followed-up for only 14 days).
The presence of the DHFR triple resistant mutant at day 0 was
not strongly associated with CD treatment failure but the high
frequency of this mutation, similar to that seen previously [30],
limited the scope to detect an association. The component drugs
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act synergistically to inhibit the enzymes in the folate pathway,
DHPS and DHFR thus making CD pharmacodynamically similar
to SP. CD was however predicted to exert less selection pressure
than SP because of its shorter plasma half-life (chlorproguanil
12.6 h, dapsone 24.5 h) compared with SP (sulfadoxine 116 h,
pyrimethamine 81 h).
We found the frequency of the *2 CYP2C19 allele in Gambians
to be similar to that in Europeans. The poor metaboliser
phenotype is much more common in Asia (approximately 20%)
due to an increased frequency of the *2 allele and the presence of
another loss of function allele *3 [11]. The *3 allele was not
present in our population and appears to be mainly confined to the
Far East. It is reassuring to note that genetic variants affecting the
activation of the chlorproguanil component of CD do not
influence clinical outcome. This may be because the metabolism
of heterozygotes is insufficiently impaired to influence levels of the
active compound. However it is interesting that we did not see an
effect in homozygotes on clinical outcome. This may simply be
because of the small numbers in our study, alternatively the drug
may be activated by another cytochrome with similar function.
Since we do not have drug levels we cannot examine this
hypothesis directly. It is perhaps more likely that the dapsone
component is responsible for the pariasite clearance in these
people. If this were so then it would tend to argue for use of CD in
combination with another antimalarial to postpone development
of resistance. It is also possible that gain of function alleles such as
the recently described *17 [12] are also present in Africa together
with previously undiscovered allelic variants. Thus a more detailed
genetic analysis of this population exploring all known functional
polymorphisms and detecting novel alleles would be important.
The parasitological failure rate of CD in this study was high. Its
slow action, evidenced by symptom clearance by day 3, could be
due to poor chlorproguanil metabolism but we failed to see an
association with the CYP2C19*2 allele. There has been relatively
little work on the pharmacogenetics of antimalarial drugs in
Africa–much of our information on potentially relevant alleles
comes from Europe and Asia. It would be useful to define the full
range of genetic variants in this population which could help to
inform policy decisions.
One third of patients treated with AL did not complete their
course of medication but despite poor adherence to the
recommended regimen, AL had excellent effectiveness up to 28
days after treatment. This is in contrast to a study in Papua New
Guinea by Schoepflin et al. [31] who attributed a high number of
treatment failures to poor adherence to complex dosing regimens
in combination with insufficient fat supplementation. In our study
the first dose was supervised, in line with best practice, although
this was not routine in most health facilities in The Gambia.
Treatment success in practice may therefore be lower than in our
trial. Adherence may be improved by interventions focusing on
provider knowledge and behavior [32], and by the use of
dispersible formulation of AL [34].This should be combined with
a message about prompt treatment-patients had symptoms for an
average of nearly 3 days before reporting to the health centre, and
mothers may wait until getting home before giving the first dose if
there is no supply of drinking water at the outpatient pharmacy.
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